This study is looking into whether ondansetron (a medicine often used to prevent nausea and vomiting in cancer patients) can help people with atrial fibrillation (Afib), which is a common irregular heartbeat. Researchers believe ondansetron might work by blocking a specific electrical current in the heart called IKas, which contributes to Afib. You might be able to join if you are between 18 and 100 years old, have Afib or atrial flutter that needs a procedure called catheter ablation, and are taking blood thinners if needed. The study will measure how much Afib you experience and how well your heart rate is controlled over 28 days. The current status of this study is unclear.

Study design

This is a randomized, double-blind study involving 80 participants. Participants will either receive ondansetron or a placebo.

What's involved

You would take ondansetron 8 mg or a matched placebo orally twice daily for 28 days.

Compensation

Not stated in the trial record.

Follow-up

Your atrial fibrillation burden will be measured over the total 28-day study duration. Ventricular rate control will be measured at 7 and 14 days after starting the study drug.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.